Skip to main content
. 2018 Aug 1;10(3):110. doi: 10.3390/pharmaceutics10030110

Table 4.

Optical microscope images of ARPE-19 after dehydration in no protective conditions (dry eye), after dehydration preceded by treatment with HA formulations and cells not submitted to dehydration (medium).

Without Die Magnification 100× Crystal Violet Magnification 200× Crystal Violet Magnification 400× Cell Viability (%)
Dry Eye (negative control) graphic file with name pharmaceutics-10-00110-i001.jpg graphic file with name pharmaceutics-10-00110-i002.jpg graphic file with name pharmaceutics-10-00110-i003.jpg 50.7 ± 6.8
CR 0.30% graphic file with name pharmaceutics-10-00110-i004.jpg graphic file with name pharmaceutics-10-00110-i005.jpg graphic file with name pharmaceutics-10-00110-i006.jpg 73.4 ± 12.6
HA 0.15% graphic file with name pharmaceutics-10-00110-i007.jpg graphic file with name pharmaceutics-10-00110-i008.jpg graphic file with name pharmaceutics-10-00110-i009.jpg 62.7 ± 9.5
HA 0.30% graphic file with name pharmaceutics-10-00110-i010.jpg graphic file with name pharmaceutics-10-00110-i011.jpg graphic file with name pharmaceutics-10-00110-i012.jpg 72.5 ± 6.2
Medium (positive control) graphic file with name pharmaceutics-10-00110-i013.jpg graphic file with name pharmaceutics-10-00110-i014.jpg graphic file with name pharmaceutics-10-00110-i015.jpg 100.0 ± 11.0